Abstract
BackgroundConsidering the potential of p16 as a marker for diagnosis, prognosis and therapeutic response, the aim of this study was to assess its presence, via immunocytochemistry, in metastatic carcinoma of different primary sites and histological types obtained from effusions and peritoneal washings. A total of 118 samples including 85 of metastatic carcinoma and 33 samples of benign effusion/peritoneal washing were prepared by the plasma/thromboplastin method. Immunocytochemistry reactions were performed on cell block sections using antibodies against p16, claudin-4, MOC-31, calretinin, HBME and CD68.ResultsP16 overexpression was observed in 88.23% of all carcinoma samples. All cervix adenocarcinoma samples showed p16 overexpression. Overexpression in adenocarcinomas of ovary, lung and breast was observed in 93.75, 93.10 and 75% of the samples, respectively. Overexpression was observed in all different histological types analyzed: small cell carcinoma (lung), squamous cell carcinoma (cervical) and urothelial carcinoma (bladder). The specificity of p16 for carcinoma detection was of 96.96%.ConclusionOverexpression of p16 was observed in most metastatic carcinoma, from different primary sites and histological types, obtained from effusions and peritoneal washings. Due to its high frequency of overexpression in metastatic carcinoma, p16 may play a possible role in tumor progression and it may be considered as a complementary diagnostic marker depending on histological type and primary site of carcinoma.
Highlights
Considering the potential of p16 as a marker for diagnosis, prognosis and therapeutic response, the aim of this study was to assess its presence, via immunocytochemistry, in metastatic carcinoma of different primary sites and histological types obtained from effusions and peritoneal washings
The use of markers for diagnosis, prognosis and therapeutic response may be necessary in follow up of patients with metastatic carcinoma obtained from effusion/peritoneal washing
Considering its potential as a marker for diagnosis, prognosis and therapeutic response and since it has not been yet reported in the literature, the aim of this study was to assess immunoreactivity for p16 in metastatic carcinoma from different primary sites and histological types obtained from effusions and peritoneal washings
Summary
Considering the potential of p16 as a marker for diagnosis, prognosis and therapeutic response, the aim of this study was to assess its presence, via immunocytochemistry, in metastatic carcinoma of different primary sites and histological types obtained from effusions and peritoneal washings. The use of markers for diagnosis, prognosis and therapeutic response may be necessary in follow up of patients with metastatic carcinoma obtained from effusion/peritoneal washing. The p16 tumor suppressor gene is a member of the INK4 (Cyclin-dependent Kinase 4 Inhibitor) class of cell cycle inhibitors [1]. Most ovarian/tubal high-grade serous carcinomas are diffusely positive for p16, while low-grade serous, endometrioid, clear cell and mucinous carcinomas are usually negative or focally positive [7, 8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
